CHWALISZ Kristof
No ORCID on file
· 110 papers in corpus
· active 1996-2009
Frequent coauthors
- ELGER WALTER 60
- SCHUBERT GERD 60
- STOECKEMANN KLAUS 30
- HAENDLER Bernard 20
- HESS-STUMP Holger 20
- LESSEY Bruce 20
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …